Article
Discordance Between FIB-4 and BAST Fibrosis Risk Classifications in Obese Patients With MASLD: Results From the OBREDI-TR Study
2026-01-09
Abstract excerpt
<h4>Background: </h4> /Objectives: Non-invasive fibrosis scores are widely used for risk stratification in metabolic dysfunction–associated steatotic liver disease (MASLD); however, their performance in obese individuals remains controversial. The Fibrosis-4 index (FIB-4) is commonly recommended as a first-line tool, yet may underestimate fibrosis risk in severe obesity. The BAST score, which incorporates metaboli...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ce44b372-f785-5563-af0e-d0eb6de8bc35
- DOI
- 10.20944/preprints202601.0621.v1
